The Medical Letter on Drugs and Therapeutics
Regorafenib (Stivarga) for Metastatic Colorectal Cancer and GIST (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Regorafenib (Stivarga – Bayer), a multikinase inhibitor, has been approved by the FDA for treatment of patients with metastatic colorectal cancer previously treated with multiple other regimens specified in the labeling. It has also been approved for use in treatment-refractory, locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST).

CLINICAL STUDIES — Metastatic Colorectal Cancer – Approval of regorafenib for metastatic colorectal cancer was based on a placebo-controlled, double-blind trial in 760 patients with previously treated metastatic colorectal cancer. Patients were randomized 2:1 to treatment with 160 mg of regorafenib or placebo for the first 21 days of each 28-day cycle. Both median overall survival (6.4 months vs. 5.0 months) and median progression-free survival (1.9 months vs. 1.7 months) were significantly longer with regorafenib than with placebo. ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Regorafenib (Stivarga) for Metastatic Colorectal Cancer and GIST (online only)
Article code: 1415c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian